Patent Reform Bill Moves to Senate; Biotech, University Groups Provide Measured Support

Biotech, pharmaceutical, and higher education organizations that previously opposed the bill are now voicing measured support for it after this week's markup addressed one of the bill's most controversial sections on apportionment of royalty damages in patent-infringement litigation.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.